重症患者早期高胆红素血症的发生率、临床特征与结局:MARS研究启示
本研究为前瞻性多中心队列研究的post hoc分析,纳入ICU入科2天内测定胆红素且排除肝硬化的患者。4,836例中559例(11.6%)出现早期高胆红素血症(入ICU 2天内胆红素≥33 μmol/L)。这些患者病情更重,脓毒症和器官衰竭发生率更高。校正混杂后,早期高胆红素血症与30天死亡相关(OR 1.31,95%CI 1.06-1.60,P=0.018),但该关联仅见于合并血小板减少者(OR 2.61,95%CI 2.08-3.27,P<0.001),血小板正常者无显著关联(OR 1.09,95%CI 0.75-1.55,P=0.655)。
要点
- ICU入科2天内胆红素≥33 μmol/L定义为早期高胆红素血症,发生率11.6%(559/4,836),肝硬化患者被排除。
- 早期高胆红素血症者病情更重,脓毒症和器官衰竭发生率更高,30天死亡风险独立升高(OR 1.31,95%CI 1.06-1.60,P=0.018)。
- 死亡关联仅存在于合并血小板减少的早期高胆红素血症患者(OR 2.61,95%CI 2.08-3.27,P<0.001;交互P=0.005)。
- 早期高胆红素血症但血小板正常者,30天死亡风险无显著升高(OR 1.09,95%CI 0.75-1.55,P=0.655)。
- 床旁对入ICU 2天内胆红素≥33 μmol/L者应警惕,尤其合并血小板减少时死亡风险更高,需加强监测。
适用人群与场景
- ICU入科2天内测定胆红素水平的危重症患者;排除肝硬化患者。
诊断标准与关键阈值
- 早期高胆红素血症定义:入ICU 2天内胆红素≥33 μmol/L。
- 血小板减少:原文未给出具体界值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 早期高胆红素血症合并血小板减少提示30天死亡风险显著升高(OR 2.61,95%CI 2.08-3.27,P<0.001)。
研究设计与关键结果
- 研究类型:前瞻性多中心队列研究的post hoc分析;样本量4,836例,肝硬化排除。
- 早期高胆红素血症发生率11.6%(559/4,836);这些患者病情更重,脓毒症和器官衰竭发生率更高。
- 校正混杂后,早期高胆红素血症与30天死亡相关:OR 1.31(95%CI 1.06-1.60),P=0.018。
- 合并血小板减少者死亡风险更高:OR 2.61(95%CI 2.08-3.27),P<0.001;交互P=0.005。
- 血小板正常者无显著关联:OR 1.09(95%CI 0.75-1.55),P=0.655。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究的post hoc分析;原文未给出证据等级或推荐强度。
- 局限:post hoc分析;原文未提及具体中心数;关联性研究,不能推断因果;血小板减少界值未给出。
对床旁实践的改变
- 对ICU入科2天内胆红素≥33 μmol/L的患者,应认识到其病情更重、脓毒症和器官衰竭更多,需加强监测。
- 合并血小板减少的早期高胆红素血症患者30天死亡风险显著升高,可能需更积极评估和处理;血小板正常者风险未见显著升高。
- 该关联为观察性研究结果,不能作为治疗决策的唯一依据;原文未提供针对高胆红素血症的特异性干预措施。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the incidence, clinical characteristics and outcomes of early hyperbilirubinemia in critically ill patients.
DESIGN AND SETTING: This is a post hoc analysis of a prospective multicenter cohort study.
PATIENTS: Patients with measured bilirubin levels within the first 2 days after ICU admission were eligible. Patients with liver cirrhosis were excluded.
ENDPOINTS: The primary endpoint was the incidence of early hyperbilirubinemia, defined as bilirubin ≥33 μmol/L within 2 days after ICU admission. Secondary endpoints included clinical characteristics of patients with versus patients without early hyperbilirubinemia, and outcomes up to day 30.
RESULTS: Of 4,836 patients, 559 (11.6%) patients had early hyperbilirubinemia. Compared to patients without early hyperbilirubinemia, patients with early hyperbilirubinemia presented with higher severity of illness scores, and higher incidences of sepsis and organ failure. After adjustment for confounding variables, early hyperbilirubinemia remained associated with mortality at day 30 (odds ratio, 1.31 [95%-confidence interval 1.06-1.60]; P = 0.018). Patients with early hyperbilirubinemia and thrombocytopenia (interaction P-value = 0.005) had a higher likelihood of death within 30 days (odds ratio, 2.61 [95%-confidence interval 2.08-3.27]; P < 0.001) than patients with early hyperbilirubinemia and a normal platelet count (odds ratio, 1.09 [95%-confidence interval 0.75-1.55]; P = 0.655).
CONCLUSIONS: Early hyperbilirubinemia occurs frequently in the critically ill, and these patients present with higher disease severity and more often with sepsis and organ failures. Early hyperbilirubinemia has an association with mortality, albeit this association was only found in patients with concomitant thrombocytopenia.
参考来源
- Juschten J, Bos LDJ, de Grooth HJ, et al. Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study. Shock. 2022. PMID: 34238904. doi:10.1097/SHK.0000000000001836
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。